Drug intelligence / Profile preview

UI-068

Development stage: Unknown
Lead developer: Korea United Pharm
Modality: Small Molecules
Administration: Oral

Overview

UI-068 is a small molecule, incrementally modified fixed-dose combination drug developed by Korea United Pharm for the treatment of type 2 diabetes mellitus. It is classified as a chemical drug and has reached the NDA/BLA (New Drug Application/Biologics License Application) stage in South Korea. While its precise mechanism of action remains undisclosed in public sources, it is being investigated primarily for endocrinology and metabolic diseases, with diabetes mellitus as its main indication. Some sources also suggest potential neuroprotective effects that could make it useful in neurodegenerative diseases[1][3][4][9].

Brand names: Linag Duo
Other names: linagliptin + metformin

Targets

DPP-4 (Dipeptidyl Peptidase-IV)AMPK (Adenosine monophosphate–activated protein kinase)GPD2 (Glycerol-3-phosphate dehydrogenase 2)

Beyond the preview

Go deeper on UI-068.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI-068.

Explore the full profile